Publications

Comparing movement patterns and physical function between chronic low back pain patients with nociplastic and nociceptive pain categories

E Archibeck, N Harris, P Zheng, A Scheffler, W Mehling, C O'Neill, J Lotz, et al.

JOR Spine 9 (1), e70166

Extracting adverse event nature, severity, timelines and resulting interventions from clinical notes of patients receiving CAR-T therapy using large language models

J Guillot, B Miao, A Suresh, M Sushil, CYK Williams, R Vashisht, et al.

medRxivPreprint

Scalable diabetes preventive care through household risk stratification using electronic health records

R Vashisht

JAMA Network Open 9 (1), e2551753

Phenome-wide risk evaluation of GLP-1 receptor agonist use in type 2 diabetes with real-world data across multiple healthcare systems

R Vashisht, SS Dhruva, A Patel, L Dahm, P Morris, D Gonzalez, R Follett, et al.

medRxivPreprint

Real-world type 2 diabetes second-line treatment allocation among patients

J Davidson, R Vashisht, K Radtke, A Patel, SK Koliwad, AJ Butte

medRxivPreprint

Characterisation of digital therapeutic clinical trials: a systematic review with natural language processing

BY Miao, M Sushil, A Xu, M Wang, D Arneson, E Berkley, M Subash, et al.

The Lancet Digital Health 6 (3), e222–e229

AI predicts early relapse post-axicabtagene ciloleucel in diffuse large B-cell lymphoma patients in a multi-center real-world study

M Wang, KV Komanduri, D Datta, A Patel, B Whitaker, A Belov, B Rubin, et al.

Blood 144, 390Conference abstract

Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational network study

EA Voss, A Shoaibi, LYH Lai, C Blacketer, T Alshammari, R Makadia, et al.

eClinicalMedicine 58

Second-line pharmaceutical treatments for patients with type 2 diabetes

R Vashisht, A Patel, L Dahm, C Han, KE Medders, R Mowers, et al.

JAMA Network Open 6 (10), e2336613

Toward a causal model of chronic back pain: challenges and opportunities

JR Huie, R Vashisht, A Galivanche, C Hadjadj, S Morshed, AJ Butte, et al.

Frontiers in Computational Neuroscience 16, 1017412

Real-world performance of SARS-CoV-2 serology tests in the United States, 2020

CV Rodriguez-Watson, AM Louder, C Kabelac, CM Frederick, NE Sheils, et al.

PLoS One 18 (2), e0279956

Evaluation of social determinants of health on type 2 diabetes treatment selection and disease severity

J Davidson, R Vashisht, A Butte

Value in Health 26 (6), S229Conference abstract

Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States

CV Rodriguez-Watson, NE Sheils, AM Louder, EH Eldridge, ND Lin, et al.

PLoS One 18 (2), e0281365

From genes to geography, from cells to community, from biomolecules to behaviors: the importance of social determinants of health

J Davidson, R Vashisht, AJ Butte

Biomolecules 12 (10), 1449

Identification of antiviral antihistamines for COVID-19 repurposing

LR Reznikov, MH Norris, R Vashisht, AP Bluhm, D Li, YSJ Liao, A Brown, et al.

Biochemical and Biophysical Research Communications 538, 173–179

Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry

DH Kwon, R Vashisht, HT Borno, RR Aggarwal, EJ Small, AJ Butte, et al.

Annals of Oncology 32 (5), 678

Age- and sex-associated variations in the sensitivity of serological tests among individuals infected with SARS-CoV-2

R Vashisht, A Patel, BO Crews, OB Garner, L Dahm, C Wilson, AJ Butte

JAMA Network Open 4 (2), e210337

Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: a University of California Health System registry study

D Kwon, R Vashisht, H Borno, RR Aggarwal, EJ Small, A Butte, et al.

Journal of Clinical Oncology 39 (6_suppl), 37Conference abstract

Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network

Q Wang, JM Reps, KF Kostka, PB Ryan, Y Zou, EA Voss, PR Rijnbeek, et al.

PLoS One 15 (1), e0226718

Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis

Y Kim, Y Tian, J Yang, V Huser, P Jin, CG Lambert, H Park, SC You, et al.

Scientific Reports 10 (1), 11115

Treatment patterns for chronic comorbid conditions in patients with cancer using a large-scale observational data network

R Chen, P Ryan, K Natarajan, T Falconer, KD Crew, CG Reich, et al.

JCO Clinical Cancer Informatics 4, 171–183

CovidCounties is an interactive real time tracker of the COVID-19 pandemic at the level of US counties

D Arneson, M Elliott, A Mosenia, B Oskotsky, S Solodar, R Vashisht, et al.

Scientific Data 7 (1), 405

Assessment of safety and effectiveness for pediatric patients of cryoanalgesia compared to epidural for the Nuss procedure in real-world data from electronic health records

BS Glicksberg, R Mora, S Rensi, VA Rudrapatna, AM Bishara, E Gress, et al.

PreprintPreprint

Host-response-based gene signatures for tuberculosis diagnosis: a systematic comparison of 16 signatures

H Warsinske, R Vashisht, P Khatri

PLoS Medicine 16 (4), e1002786

Impact of integrated psycho-socio-economic support on treatment outcome in drug resistant tuberculosis: a retrospective cohort study

R Bhatt, K Chopra, R Vashisht

Indian Journal of Tuberculosis 66 (1), 105–110

Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes

R Vashisht, K Jung, A Schuler, JM Banda, RW Park, S Jin, L Li, JT Dudley, et al.

JAMA Network Open 1 (4), e181755

Integrated molecular, clinical, and ontological analysis identifies overlooked disease relationships

WA Haynes, R Vashisht, F Vallania, C Liu, GL Gaskin, E Bongen, et al.

bioRxiv 214833Preprint

Learning effective treatment pathways for type 2 diabetes from a clinical data warehouse

R Vashisht, K Jung, N Shah

AMIA Annual Symposium Proceedings 2016, 2036–2045

Metformin as a potential combination therapy with existing front-line antibiotics for tuberculosis

R Vashisht, SK Brahmachari

Journal of Translational Medicine 13 (1), 83

Systems level mapping of metabolic complexity in Mycobacterium tuberculosis to identify high-value drug targets

R Vashisht, AG Bhat, S Kushwaha, A Bhardwaj, OSDD Consortium, et al.

Journal of Translational Medicine 12 (1), 263

Social networks to biological networks: systems biology of Mycobacterium tuberculosis

R Vashisht, A Bhardwaj, OSDD Consortium, SK Brahmachari

Molecular BioSystems 9 (7), 1584–1593

Crowd sourcing a new paradigm for interactome driven drug target identification in Mycobacterium tuberculosis

R Vashisht, AK Mondal, A Jain, A Shah, P Vishnoi, P Priyadarshini, et al.

PLoS One 7 (7), e39808

Software platform for metabolic network reconstruction of Mycobacterium tuberculosis

S Ghosh, Y Matsuoka, Y Asai, H Kitano, A Bhardwaj, V Scaria, R Vashisht, et al.

Systems Biology of Tuberculosis, 21–35Book chapter

Protein–protein interaction networks suggest different targets have different propensities for triggering drug resistance

J Padiadpu, R Vashisht, N Chandra

Systems and Synthetic Biology 4 (4), 311–322

Modeling metabolic adjustment in Mycobacterium tuberculosis upon treatment with isoniazid

AG Bhat, R Vashisht, N Chandra

Systems and Synthetic Biology 4 (4), 299–309

Strategies for efficient disruption of metabolism in Mycobacterium tuberculosis from network analysis

K Raman, R Vashisht, N Chandra

Molecular BioSystems 5 (12), 1740–1751